Results 281 to 290 of about 365,877 (337)

Management of Treatment Resistant EGFR Inhibitor‐Induced Papulopustular Exanthema With Isotretinoin and Dapsone

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Epidermal growth factor receptor inhibitors (EGFRi) commonly cause papulopustular exanthemas that may compromise the success of cancer therapy. While tetracyclines are first‐line treatment, data on alternative systemic agents for refractory cases remain limited.
Ishana Dixit, Raquel Ruiz Araujo, Pablo Fernandez‐Peñas   +2 more
wiley   +1 more source

nab-paclitaxel/carboplatin induction in squamous NSCLC: Longitudinal quality of life while on chemotherapy [PDF]

, 2017
et al,, Morgensztern, Daniel
core   +1 more source

Bidirectional Mendelian randomization identifies differential causal associations between inflammatory cytokines and lung cancer subtypes. [PDF]

Discov Oncol
Sun M, Gao X.
europepmc   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

EGFR Mutations and Tyrosine Kinase Inhibitors: Structural Insights and Therapeutic Advances. [PDF]

ACS Omega
Manoj MV, Mupparaju V RB, Thakur A, Sasidharan Pillai AK.   +3 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer [PDF]

, 2018
Bradley, Jeffrey D, Roach, Michael C, Robinson, Cliff G   +2 more
core   +1 more source

Dacomitinib as a First-Line Therapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study. [PDF]

Cancer Med
Hsu PC, Ko HW, Chiu LC, Huang SH, Lee CS, Lin YC, Kuo SC, Ju JS, Wang CC, Yang CT.   +9 more
europepmc   +1 more source

TNMplot: An enhanced platform for pharmacological target identification through cross‐stage and pan‐cancer gene expression analysis

British Journal of Pharmacology, EarlyView.
TNMplot.com, a web‐based platform integrating RNA‐Seq and gene‐chip data from 56,938 samples, enables differential gene expression analysis across normal, primary tumour and metastatic tissues, facilitating large‐scale transcriptomic profiling across 22 tumour types.
Áron Bartha, Balázs Győrffy
wiley   +1 more source